Shionogi to buy U.S. pharmaceutical firm Sciele Pharma

Shionogi to buy U.S. pharmaceutical firm Sciele Pharma

TOKYO, Japan - Isao Teshirogi (R), president of Japanese drug manufacturer Shionogi & Co., poses with Patrick Fourteau, chief executive of Sciele Pharma Inc., at a news conference in Tokyo on Sept. 1, in which Shionogi announced that it will launch a $1.1 billion friendly offer for shares in the Atlanta-based U.S. pharmaceutical company in order to establish a sales base in the United States.

  • Product Code
  • ILEA001129642
  • Registered date
  • 2008/9/01 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2008 Kyodo News
  • Media size
  • 1740 × 1303 pixel
  • Resolution
  • 240 dpi
  • Deployment size
  • 543.39(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Sompo CEO to step down over Bigmotor insurance fraud scandal

    Sompo CEO to step down over Bigmotor insurance fraud scandal

    Major Japanese insurance firm Sompo Holdings Inc. CEO Kengo Sakurada (R) bows at a press conference in Tokyo on Jan. 26, 2024, and announces he intends to step down at the end of March to take responsibility for the company's involvement in used car dealer Bigmotor Co.'s insurance fraud scandal.
      Johnny's talent agency sex abuse scandal

      Johnny's talent agency sex abuse scandal

      Julie Keiko Fujishima (R), former president of Johnny & Associates Inc., and its new president Noriyuki Higashiyama attend a press conference in Tokyo on Sept. 7, 2023, amid allegations the major Japanese talent agency's late founder and her uncle Johnny Kitagawa had sexually abused teenagers aspiring to become pop singers for decades.
        U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

        U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

        Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
          U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

          U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

          Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
            U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

            U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

            Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
              DHL Japan President Tony Khan

              DHL Japan President Tony Khan

              DHL Japan Inc. President Tony Khan speaks at a press conference in Tokoname in Aichi Prefecture on Sept. 13, 2022. The company announced a doubling of the number of cargo flight round trips between Chubu airport in the central Japan city and the United States to six a week from Sept. 6.
                Japanese drugmaker Shionogi's president

                Japanese drugmaker Shionogi's president

                Isao Teshirogi, president of Japanese pharmaceutical firm Shionogi & Co., attends a press conference in Tokyo on March 4, 2022, over the company's COVID-19 vaccine under development.
                  Japanese drugmaker Shionogi's president

                  Japanese drugmaker Shionogi's president

                  Isao Teshirogi (C), president of Japanese pharmaceutical firm Shionogi & Co., attends a press conference in Tokyo on March 4, 2022, over the company's COVID-19 vaccine under development.
                    Mitsubishi Chemical HD to make Mitsubishi Tanabe Pharma Corporation a wholly owned subsidiary

                    Mitsubishi Chemical HD to make Mitsubishi Tanabe Pharma Corporation a wholly owned subsidiary

                    Mitsubishi Chemical Holdings (HD) announced on the 18th that it will invest up to 491.8 billion yen to make its consolidated subsidiary Mitsubishi Tanabe Pharma Corporation a wholly owned subsidiary. Currently, MCHC holds 56.39% of Mitsubishi Tanabe Pharma's shares, and will conduct a tender offer from January 19 to January 7, 2020, aiming to make Mitsubishi Tanabe Pharma its wholly owned subsidiary. At a press conference in Tokyo on January 18, MCHC President Hitoshi Ochi said, "The world is evolving greatly and healthcare is developing at a very fast pace. Mitsubishi Tanabe Pharma will also accelerate the overseas development of promising new drug candidates by using MCHC's human resources. The company will utilize the diverse resources of a comprehensive chemical manufacturer to efficiently create new businesses and enhance the earnings structure of a core healthcare company. (November 18, 2019, Tokyo, Japan; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
                      Honda's group net profit down for 1st time in 3 yrs

                      Honda's group net profit down for 1st time in 3 yrs

                      TOKYO, April 28 Kyodo - Tetsuo Iwamura, executive vice president of Honda Motor Co., announces the company's earnings results for the year ended in March 2015 at a press conference in Tokyo on April 28, 2015. Honda's group net profit fell for the first time in three years, down 8.9 percent from a year earlier to 522.76 billion yen ($4.4 billion), hurt by recall-related costs and sluggish sales in Japan.